In the conclusion, we provide specific suggestions on how to upregulate LPS clearance to control TLR4-mediated inflammation, offering valuable strategies that could lead to novel therapeutic approaches for managing endotoxemia. The gene discussed is TLR4; the disease is serum lipopolysaccharide activity.